I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars.
“Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent, enabling legal 
distribution before patent expiration. As a result, the Biotechnology Industry Organization, as well as the handful of biotechs that control most of the market, supports a 14-year period to allow companies to recoup their investment and conduct further clinical trials to improve the product.”
Is everyone in the business going to the copy cat system since the price of bringing new drugs to market is so high? It certainly looks like it can bring some interesting issues to the table when it comes to patents and intelligent property in the future. BD
This is what it’s come to: Pfizer, the flagship of the American brand-name drug industry, is moving into generics in a big way.
Yes, the company’s Greenstone unit has quietly been turning out generic versions of some of Pfizer’s own off-patent products for a while. But now the company wants to be a bigger player in the rough-and-tumble, low-margins generics business — and plans to start selling generic versions of competitors’ off-patent drugs, Dow Jones Newswires reports. It sounds like the company plans to pick its spots. Pfizer is looking at niche products such as certain hard-to-make injectable drugs, as well as new formulations, such as a form of Xanax that dissolves under the tongue, DJ Newswires reports.
And on this note I had to include a bit of humor from the Today Show, one of my favorites addressing the topic of generic drugs. BD
Related Reading:
0 comments :
Post a Comment